Generic Tuxarin ER Availability
Last updated on Nov 6, 2024.
Tuxarin ER is a brand name of chlorpheniramine/codeine, approved by the FDA in the following formulation(s):
TUXARIN ER (chlorpheniramine maleate; codeine phosphate - tablet, extended release;oral)
-
Manufacturer: MAINPOINTE
Approval date: June 22, 2015
Strength(s): 8MG;54.3MG
Has a generic version of Tuxarin ER been approved?
No. There is currently no therapeutically equivalent version of Tuxarin ER available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tuxarin ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
Patent 9,066,942
Issued: June 30, 2015
Inventor(s): Giliyar Chandrashekar & Nachaegari Satish Kumar & Nachiappan Chidambaram & Patel Mahesh V. & Venkateshwaran Srinivansan
Assignee(s): Spriaso LLCThe disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10moles to about 2.0×10moles.
Patent expiration dates:
- January 3, 2032✓
- January 3, 2032
-
Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Patent 9,107,921
Issued: August 18, 2015
Inventor(s): Giliyar Chandrashekar & Nachaegari Satish Kumar & Machiappan Chidambaram & Patel Mahesh V. & Venkateshwaran Srinivasan
Assignee(s): Spriaso LLCA pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cm˜ for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cm˜ provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.
Patent expiration dates:
- January 3, 2032✓
- January 3, 2032
More about Tuxarin ER (chlorpheniramine / codeine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: upper respiratory combinations
- En español
Patient resources
Other brands
Lexuss 210, Codar AR, Codeprex, Tuzistra XR, Z-Tuss AC
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.